FullText URL fulltext.pdf
Author Suzuki, Yoko| Taniguchi, Kohei| Hatono, Minami| Kajiwara, Yukiko| Abe, Yuko| Kawada, Kengo| Tsukioki, Takahiro| Kochi, Mariko| Nishiyama, Keiko| Iwamoto, Takayuki| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Tabata, Masahiro| Yanai, Hiroyuki| Doihara, Hiroyoshi|
Keywords Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma
Published Date 2020-01-16
Publication Title Surgical Case Reports
Volume volume6
Issue issue1
Publisher SpringerOpen
Start Page 25
ISSN 2198-7793
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s). 2020
File Version publisher
PubMed ID 31950295
DOI 10.1186/s40792-020-0790-7
Web of Science KeyUT 000513920900001
Related Url isVersionOf https://doi.org/10.1186/s40792-020-0790-7
JaLCDOI 10.18926/AMO/56873
FullText URL 73_3_279.pdf
Author Makimoto, Go| Nishimori, Hisakazu| Kondo, Reiko| Yanai, Hiroyuki| Sugimoto, Morito| Oda, Naohiro| Kubo, Toshio| Hotta, Katsuyuki| Tabata, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu|
Abstract Urothelial carcinoma usually presents with hematuria, but cases of multiple lymphadenopathy with elevated S-pancreas-1 antigen (SPan-1) levels have not been reported. A 62-year-old Japanese man with lymphadenopathies was diagnosed with an adenocarcinoma of unknown origin and transferred to our hospital for further diagnosis. Serum carbohydrate antigen 19-9 and SPan-1 levels were extremely elevated. Uroplakin III immunostaining was positive in the inguinal lymph node, and cystoscopy revealed the presence of invasive urothelial carcinoma. Treatment with cisplatin and gemcitabine promoted a complete metabolic response for > 4 years. The detection of uroplakin III and serum SPan-1 might help diagnose urothelial carcinoma.
Keywords urothelial carcinoma uroplakin III s-pancreas-1 antigen carbohydrate antigen 19-9 chemotherapy
Amo Type Case Report
Published Date 2019-06
Publication Title Acta Medica Okayama
Volume volume73
Issue issue3
Publisher Okayama University Medical School
Start Page 279
End Page 284
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31235978
JaLCDOI 10.18926/AMO/56080
FullText URL 72_3_319.pdf
Author Makimoto, Go| Ichihara, Eiki| Hotta, Katsuyuki| Ninomiya, Kiichiro| Oze, Isao| Minami, Daisuke| Ninomiya, Takashi| Kubo, Toshio| Ohashi, Kadoaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
Keywords cisplatin mannitol furosemide lung cancer hydration non-small cell lung cancer
Amo Type Clinical Study Protocol
Published Date 2018-06
Publication Title Acta Medica Okayama
Volume volume72
Issue issue3
Publisher Okayama University Medical School
Start Page 319
End Page 323
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29926012